Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Australia’s December Trade Surplus Expands but Falls Short of Expectations 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Global pharmaceutical stocks dropped sharply Monday after former U.S. President Donald Trump pledged to cut prescription drug prices by up to 59% to align with prices in other wealthy countries. The announcement came via a Truth Social post, following a similar promise made just a day earlier, citing a potential 30% to 80% reduction “almost immediately.”
Major U.S. drugmakers including AbbVie, Amgen, Pfizer, Eli Lilly, and Merck fell between 2.2% and 3.7% in premarket trading. Biotech shares also declined amid fears of heightened regulatory scrutiny and pricing pressure. Jefferies analyst Michael Yee noted the sector could see increased volatility due to policy uncertainty.
Trump’s proposal aims to address the high cost of medications in the U.S., which often pays nearly triple the price compared to other developed nations. However, details on how the proposed cuts will be implemented remain unclear. Leerink Partners analyst David Risinger emphasized the need for clarity on the timeline and affected government programs.
European pharmaceutical stocks also took a hit, with a healthcare index dropping 2.9%. AstraZeneca, GSK, and Roche declined between 3.3% and 6.8%. Analysts warn the move could influence EU-U.S. trade negotiations, potentially substituting tariffs with pharmaceutical price caps.
India’s Biocon and Lupin slid as the U.S. remains their largest export market. In Australia, CSL Ltd and Mayne Pharma fell as healthcare stocks dropped to a multi-week low. Japan’s pharma sector plummeted 6.5%, with Daiichi Sankyo losing over 8%, marking it the worst-performing sector on the Tokyo Exchange. In Hong Kong, Alphamab Oncology tumbled 14.4%.
The global sell-off comes as the U.S. and China agree to ease mutual tariffs, signaling potential shifts in trade dynamics and global market sentiment.
